Multiple Sclerosis Therapeutic Market Size

Multiple Sclerosis Therapeutic Market size is estimated at USD 26.4 billion in 2024 and is likely to exceed USD 46.8 billion by the end of 2037, growing at over 4.9% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of multiple sclerosis therapeutic is evaluated at USD 29 billion. The increasing prevalence of multiple sclerosis globally with its rising awareness is leading to earlier diagnosis and treatment. Advancements in medical research have further resulted in the development of innovative therapies, including biologics, monoclonal antibodies, and oral treatments. These treatments offer improved efficacy and patient convenience.

As per an article posted by WHO in August 2023, over 1.8 million people around the world suffer from multiple sclerosis (MS). The disease is primarily common among young adults and females. Several companies are engaging in R&D to accelerate the development and launch of next-generation treatments to address this rising concern. For instance, in December 2022, the U.S. FDA approved Briumvi to treat adults suffering from relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. In February 2024, Neuraxpharm Group announced the launch of Briumvi in Europe. Additionally, the trend toward personalized medicines is gaining traction as patients and healthcare providers seek more tailored therapeutic approaches.